Investor Presentaiton
SELECT TRIALS - IMLUNESTRANT
Study
Indication*
Title
Phase Patients
Primary Outcome*
**
Lilly
Primary
Completion
Completion
Breast
NCT04975308
Neoplasms
Study of Imlunestrant, Investigator's Choice of Endocrine
Therapy, and Imlunestrant Plus Abemaciclib in
Participants With ER+, HER2- Advanced Breast Cancer
(EMBER-3)
3
860
Progression Free Survival (PFS) in the Intent-to-Treat (IIT)
Population
Apr 2024
Aug 2027
NCT05514054
Breast
Neoplasms
A Study of Imlunestrant Versus Standard Endocrine
Therapy in Participants With Early Breast Cancer (EMBER- 3
4)
6000
Invasive Disease-Free Survival (IDFS)
Oct 2027
Mar 2032
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
Source: clinicaltrials.gov, July 17, 2023
2023 Q2 EARNINGS
39View entire presentation